Home Tags PermaLink

Tag: PermaLink

Glythera and Cancer Research UK Collaborate in the Development of “Next-Gen”...

Cancer Research UK and Glythera, a company developing the "next-gen" antibody-drug conjugates or ADCs have agreed that Glythera receives exclusive, worldwide rights, to the...

Glythera Wins Grant to Develops Portfolio of PermaLink®-based ADCs

Glythera, a UK-based company has won a UK £ 1 million (US $ 1,12 million) Innovate UK grant to fund a new project to...

Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs

Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...

DOWNLOAD